<?xml version="1.0" encoding="UTF-8"?>
<p id="p0195">Based on the drugs approved by FDA between 2009 to 2018, the mean research and development investment required to bring a new drug to the market was estimated to be $1336 million (M), and the median was estimated to be $985M [
 <xref rid="bib152" ref-type="bibr">152</xref>]. The major components of cost driver include product development, facilities and equipment, direct labor, overhead, and licensing and commercialization [
 <xref rid="bib153" ref-type="bibr">153</xref>]. In product development, the estimated cost range &gt;500M USD with the risk-adjusted cost of 135–350M USD. In facilities and equipment, the estimated cost range between 50 to 700M USD. Direct labor and overhead cost range has been estimated to be 25% less than of total manufacturing costs, and up to 45% of labor and raw materials cost combined together respectively. For licensing and commercialization, the WHO process 300 (thousand) K USD for a site audit, 25K–100K USD for evaluation and annual fees of 4.8K–140K USD [
 <xref rid="bib154" ref-type="bibr">154</xref>, 
 <xref rid="bib155" ref-type="bibr">155</xref>, 
 <xref rid="bib156" ref-type="bibr">156</xref>]. mRNA-1273 being developed by Moderna has received funding of $483M in April and $472M in July with total funding of $955M approximately whereas another leading vaccine, ChAdOx1 being developed by University of Oxford has received funding of £84M approximately [
 <xref rid="bib159" ref-type="bibr">159</xref>].
</p>
